Is BriaCell Therapeutics Corp. Warrant (BCTXZ) a Buy, Sell, or Hold?
NASDAQ : BCTXZ
BriaCell Therapeutics Corp. Warrant
$0.0999 USD
$0.0 (2.88%)
- Volume
- 215.35K
- Average Volume
- 126.9K
- Market Capitalization
- $188.19K
- P/E Ratio
- -0.28
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.13
- Year Low
- $0.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.07
Company Overview
NASDAQ
William V. Williams
Biotechnology
Healthcare
BCTXZ
16
CA
USD
Liquidity Metrics
0.00
7.07
7.07
1.92
0.00
Sales & Valuation
-$
0.00
1.03
-0.96
-4.28
Profitability
-$62.95
-$26.63M
0.00%
0.00%
-147.92%
-113.23%
P/E Metrics
-0.28
0.00
0.00
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-8.91
2/9
$21.8M
$27.07M
$3.66M
-$24.39M
Key Metrics (TTM)
$22.59M
0.00
-0.72
7.07
-147.92%
-136.31%
-124.79%
-105.21%
-29854 days
Company Executives
| Name | Title |
|---|---|
| Gadi Levin | Chief Financial Officer & Corporate Secretary |
| Giuseppe Del Priore | Chief Medical Officer |
| Miguel A. Lopez-Lago | Chief Scientific Officer |
| William V. Williams FCPA | Chief Executive Officer, President & Director |
| Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
Poll Results
No votes yet today — be the first to share your view!
About BriaCell Therapeutics Corp. Warrant (NASDAQ:BCTXZ) Stock
BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and develop ... ment agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.
Frequently Asked Questions
-
What is the current BriaCell Therapeutics Corp. Warrant (BCTXZ) stock price?
-
BriaCell Therapeutics Corp. Warrant(NASDAQ:BCTXZ) stock price is $0.0999 in the last trading session. During the trading session, BCTXZ stock reached the peak price of $0.125 while $0.09 was the lowest point it dropped to. The percentage change in BCTXZ stock occurred in the recent session was 2.88% while the dollar amount for the price change in BCTXZ stock was $0.0.
-
BCTXZ's industry and sector of operation?
-
The NASDAQ listed BCTXZ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCTXZ?
-
Gadi Levin | Chief Financial Officer & Corporate Secretary
Giuseppe Del Priore | Chief Medical Officer
Miguel A. Lopez-Lago | Chief Scientific Officer
William V. Williams FCPA | Chief Executive Officer, President & Director
Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board -
How many employees does BCTXZ have?
-
Number of BCTXZ employees currently stands at 16. BCTXZ operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.
-
Link for BCTXZ official website?
-
Official Website of BCTXZ is: https://www.briacell.com
-
How do I contact BCTXZ?
-
BCTXZ could be contacted at phone #604-921-1810 and can also be accessed through its website. BCTXZ operates from Bellevue Centre, West Vancouver, BC V7T 2X1, CA.
-
How many shares of BCTXZ are traded daily?
-
The average number of BCTXZ shares traded daily for last 3 months was 126.9K.
-
What is the market cap of BCTXZ currently?
-
The market value of BCTXZ currently stands at $188.19K with its latest stock price at $0.0999